You really want to pay attention to the opinions of endocrinologists. They are more an expert in the field of diabetes. Afrezza will be very useful for non-smoking Type 2 patients who are trying to impede the progress of the disease and need help beyond changing their diet.
Investors in MNKD are not going to need a short squeeze to profit from Afrezza, or any of MNKD's drugs and technologies. Time will prove Afrezza to be a top seller, and better yet will bring much needed insulin therapy to many, improving health and life for millions. Partnerships often lead to buy outs. MRK could counter losing the partnership by trying to buy MNKD out from under SNY's partnership. Even if they don't, SNY is a respected, knowledge big pharmaceutical company whose expertice will bring success. SNY might even buy out MNKD at some point. There are so many more possibilities that are positive than are negative. The old saying goes "Patience is a virtue." Trust that Afrezza and what it will do for the good of millions of diabetics is a virture, and that the patience will pay off, monetarily and in the quality of millions of people around the world.
This is the set up for a buy out by SNY and/or hopefully a bidding war in the future. This partnership is only the beginning.
The partnership is exclusive, so does that mean MNKD cannot partner with any other pharmas in other countries? I also wonder if MNKD would be attractive to be bought out by another big pharma?
Feurstein tweeting MNKD will have partnership news ought to change your mind. He is notoriously negative ...and he went positive on MNKD. He tweeted this week after the insulin agreement "we have lift off"...I am soooo ready for the rocket booster stage. Bring it on MNKD.
It is possible MNKD wants to make money on both sides, manufacturing the drug and some of the profits from sales through a partner. It is also possible MNKD's position is stronger being the manufacturer of Afreeza and can court several partners vs one.
Bloomberg reported the same thing in June. MNKD was in talks at that time. Feurstein ate crow with that article. He was not bluffing. He's got the SEC all over him right now so he's on his best behavior.
Oral does not emulate the pancreas, inhaling does. HUGE advantage. The closer to mimicking the body the better for the diabetic. But good try , HA HA
Check out Adam Feurstein's short article on July 25th. He has been negative on the stock but wrote to watch for a partnership in weeks. There's your leak.
July 25, 2014 11:43 AM EDT
'MannKind (NASDAQ: MNKD) could report Afreeza partnership news in weeks, at the latest, said theStreet's Adam Feuerstein (link).'
There could be one or several partnerships.
For those that are so sure there won't be any partnership, you might rethink.
(Updated - June 12, 2014 2:46 PM EDT)
"MannKind (NASDAQ: MNKD) in talks with partners for Afrezza. Sees 6 - 8 weeks post PDUFA date for finalize partnerships, according to Bloomberg headlines. Partnerships could be royalty-based or profit sharing."
Have you ever been to India?? If you have then deep down inside I suspect that you know what I am referring to about a large sector of the people that live in India. Yes, big numbers, but not a lot of money. And yes, I am extremely in the know on this subject. Just ask the US Census Bureau.
That is a great suggestion, and I certainly hope that they look me up. I can teach them how to make money.
To sell to a popluation that for the most part has very little to no money, and we buy their goods on the cheap, so how will AMZN sell to them with any kind of margin???? Insanity - keep doing what you have been doing and expect a different result. Yep, that's AMZN. They will sell more and more stuff, but still can't make money.
I picked up some calls yesterday, jan 2016 exp (buying time) when the stock hit 8.60 ish. I noticed the bounce off of 8.50 and figure with news of a partnership pending any day now, short positions might start exiting their positions. Technicals, as you have sited, point to covering too. Nice post, thank you.